Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals has announced that it has advanced development of a new proprietary product, called ProctiGard, for the treatment of radiation proctitis.
Subscribe to our email newsletter
Radiation proctitis (RP) is a significant unmet medical need, with no well-established standard of care. Access is actively seeking marketing partners globally for ProctiGard™.
Access Pharmaceuticals president and CEO Jeffrey B. Davis noted that the company is actively developing follow-on products to MuGard that leverage its powerful mucoadhesive polymer hydrogel drug delivery technology, and ProctiGard is the first example of this development effort.
"Radiation proctitis is a condition somewhat analogous to oral mucositis, concerning the damage and ulceration of the mucosal tissue of the digestive tract. The development of ProctiGard™ is a direct response to dialogue with the oncology community that is looking for better, more effective treatment options for this debilitating oncology side effect.
"Access intends to follow the MuGard® development and commercialization strategy with ProctiGard™ by progressing manufacturing scale-up, the signing of multiple commercialization partners here in the US and abroad, and the completion and successful publication of supportive, positive clinical data similar to the recently published MuGard® clinical trial data in Cancer," Davis added.